| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mengzhu Sun, Yong Wu, Chun Yuan, Jingya Lyu, Xinyi Zhao, Ye Chun Ruan, Jinghui Guo, Wen Qing Huang, Hui Che. Androgen-induced upregulation of CFTR in pancreatic β-cell contributes to hyperinsulinemia in PCOS model. Endocrine. 2023-11-03. PMID:37922092. |
this study aims to investigate the contribution of androgen and cftr to hypersecretion of insulin in pcos and the underlying mechanism. |
2023-11-03 |
2023-11-08 |
Not clear |
| Anneliese J Flatt, Saba Sheikh, Amy J Peleckis, Paola Alvarado, Denis Hadjiliadis, Darko Stefanovski, Robert J Gallop, Ronald C Rubenstein, Andrea Kelly, Michael R Rickel. Preservation of β-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy. The Journal of clinical endocrinology and metabolism. 2023-07-28. PMID:37503734. |
elexacaftor/tezacaftor/ivacaftor (eti; trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (cftr) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (pi-cf). |
2023-07-28 |
2023-08-14 |
Not clear |
| Fabian Lurquin, Sophie Gohy, Michel P Hermans, Vanessa Preumon. Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes. Journal of clinical & translational endocrinology. vol 33. 2023-07-14. PMID:37448650. |
this study aims to evaluate insulin requirements after initiation of combined cftr modulator therapy in patients with cf-related diabetes (cfrd) and homa indices changes in cf patients without diabetes. |
2023-07-14 |
2023-08-14 |
Not clear |
| Rikke Spragge Ekblond, Bibi Uhre Nielsen, Christine Højte, Thomas Peter Almdal, James Shaw, Tacjana Pressler, Daniel Faurholt-Jepsen, Inger Hee Mabuza Mathiese. Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment. Pediatric pulmonology. 2023-06-21. PMID:37341613. |
in the current study, we evaluated the change in glucose tolerance and insulin secretion after first-generation cftr modulator treatment in adults with cf. |
2023-06-21 |
2023-08-14 |
Not clear |
| Shubham Agarwal, Ildiko Lingvay, Sasan Mirfakhraee, Raksha Jai. Chronic Pancreatitis Associated With a Variant of AACE clinical case reports. vol 9. issue 3. 2023-05-30. PMID:37251971. |
we report the case of a patient with chronic pancreatitis who underwent a total pancreatectomy with autologous islet cell transplantation with increasing insulin requirements and its association with cystic fibrosis transmembrane conductance regulator (cftr)-related disorder. |
2023-05-30 |
2023-08-14 |
Not clear |
| Sana Hasan, Mohammad Salman Khan, M Cecilia Lansan. The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes. Journal of clinical & translational endocrinology. vol 29. 2022-06-24. PMID:35746945. |
here we review the underlying mechanisms involved in the pathogenesis of cfrd, focusing on the role of cftr in the regulation of insulin secretion from the β-cell. |
2022-06-24 |
2023-08-14 |
Not clear |
| Sana Hasan, Sarah Soltman, Colleen Wood, Scott M Blackma. The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes. Journal of clinical & translational endocrinology. vol 27. 2022-01-03. PMID:34976741. |
two groups of hypotheses have been proposed for the mechanism of cftr impairing insulin secretion in cfrd: (1) β-cell dysfunction results from β cell intrinsic cftr-dependent mechanisms of insulin secretion. |
2022-01-03 |
2023-08-13 |
Not clear |
| Lina Merjaneh, Sana Hasan, Nader Kasim, Katie Larson Od. The role of modulators in cystic fibrosis related diabetes. Journal of clinical & translational endocrinology. vol 27. 2021-12-17. PMID:34917484. |
cftr modulators might affect development or progression of cfrd through many mechanisms including improving insulin secretion by correcting the cftr defect directly, improving ductal function, reducing islet inflammation, and improving incretin secretion or by enhancing insulin sensitivity via reduced systemic inflammation and increased physical activity driven by improved lung function and quality of life. |
2021-12-17 |
2023-08-13 |
Not clear |
| Lina Merjaneh, Sana Hasan, Nader Kasim, Katie Larson Od. The role of modulators in cystic fibrosis related diabetes. Journal of clinical & translational endocrinology. vol 27. 2021-12-17. PMID:34917484. |
if the defect in insulin secretion is reversible then it is possible that initiation of cftr modulators at a younger age might help prevent cfrd. |
2021-12-17 |
2023-08-13 |
Not clear |
| Xue-Lian Zhang, Xinyi Zhao, Yong Wu, Wen-Qing Huang, Jun-Jiang Chen, Peijie Hu, Wei Liu, Yi-Wen Chen, Jin Hao, Rong-Rong Xie, Hsiao Chang Chan, Ye Chun Ruan, Hui Chen, Jinghui Gu. Angiotensin(1-7) activates MAS-1 and upregulates CFTR to promote insulin secretion in pancreatic β-cells: the association with type 2 diabetes. Endocrine connections. 2021-11-27. PMID:34825893. |
angiotensin(1-7) activates mas-1 and upregulates cftr to promote insulin secretion in pancreatic β-cells: the association with type 2 diabetes. |
2021-11-27 |
2023-08-13 |
Not clear |
| Xue-Lian Zhang, Xinyi Zhao, Yong Wu, Wen-Qing Huang, Jun-Jiang Chen, Peijie Hu, Wei Liu, Yi-Wen Chen, Jin Hao, Rong-Rong Xie, Hsiao Chang Chan, Ye Chun Ruan, Hui Chen, Jinghui Gu. Angiotensin(1-7) activates MAS-1 and upregulates CFTR to promote insulin secretion in pancreatic β-cells: the association with type 2 diabetes. Endocrine connections. 2021-11-27. PMID:34825893. |
we recently identified an important role of cftr, a camp-activated cl- channel, in regulation of insulin secretion. |
2021-11-27 |
2023-08-13 |
Not clear |
| Xue-Lian Zhang, Xinyi Zhao, Yong Wu, Wen-Qing Huang, Jun-Jiang Chen, Peijie Hu, Wei Liu, Yi-Wen Chen, Jin Hao, Rong-Rong Xie, Hsiao Chang Chan, Ye Chun Ruan, Hui Chen, Jinghui Gu. Angiotensin(1-7) activates MAS-1 and upregulates CFTR to promote insulin secretion in pancreatic β-cells: the association with type 2 diabetes. Endocrine connections. 2021-11-27. PMID:34825893. |
here, we tested possible involvement of cftr in mediating angiotensin(1-7)'s effect on insulin secretion and measured the level of angiotensin(1-7), mas-1 as well as cftr in the blood of individuals with or without type 2 diabetes. |
2021-11-27 |
2023-08-13 |
Not clear |
| N B Chagay, G Ya Khayt, T M Vdovina, A A Shaforos. [Cystic fibrosis being a polyendocrine disease (Review)]. Problemy endokrinologii. vol 67. issue 2. 2021-10-28. PMID:34004101. |
subnormal cftr activity leads to stagnation of mucociliary clearance, inhibition of intestinal transport.in addition to exocrine disorders, cftr mutations are associated with a decrease in volume, mass, increased apoptosis of β-cells of the pancreas, a significant suppression of insulin exocytosis in response to stimulation with glucose and glucagon-like peptide-1, hyperglucagonemia against the background of a defect in the suppression of α-cell function by insulin, but a decrease in maximum capacity α-cells.deficiency and progressive decline in bone mineral density is an expected secondary manifestation of cf due to pancreatic exocrine insufficiency with malabsorption of nutrients and fat-soluble vitamins. |
2021-10-28 |
2023-08-13 |
Not clear |
| C Colombo, A Foppiani, A Bisogno, S Gambazza, V Daccò, E Nazzari, A Leone, A Giana, A Mari, A Battezzat. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion. Journal of endocrinological investigation. vol 44. issue 10. 2021-09-10. PMID:33586024. |
we evaluated the variation in glucose metabolism and insulin secretion in cf patients homozygous for phe508del cftr mutation after one-year treatment with luma/iva in comparison to patients with the same genotype who did not receive such treatment. |
2021-09-10 |
2023-08-13 |
Not clear |
| Amir Moheet, Daniel Beisang, Lin Zhang, Scott D Sagel, Jill M VanDalfsen, Sonya L Heltshe, Carla Frederick, Michelle Mann, Nicholas Antos, Joanne Billings, Steven M Rowe, Antoinette Mora. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. vol 20. issue 2. 2021-08-30. PMID:32917547. |
in small pilot studies, treatment with ivacaftor improved insulin secretion in patients with the g551d cftr mutation. |
2021-08-30 |
2023-08-13 |
Not clear |
| Francesca Cirillo, Cecilia Catellani, Pietro Lazzeroni, Chiara Sartori, Gabriele Tridenti, Cristina Vezzani, Anna Maria Fulghesu, Eleonora Madeddu, Sergio Amarri, Maria E Stree. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 36. issue 7. 2021-04-01. PMID:32054355. |
high-mobility-group-box-1 (hmgb1) was shown to increase in pcos patients as a consequence of reduced cystic-fibrosis-transmembrane-conductance-regulator (cftr) expression in the ovary, and was associated with insulin resistance and inflammation, both features of pcos. |
2021-04-01 |
2023-08-13 |
human |
| Junzhong Gu, Weiwei Zhang, Lida Wu, Yuchun G. CFTR Deficiency Affects Glucose Homeostasis via Regulating GLUT4 Plasma Membrane Transportation. Frontiers in cell and developmental biology. vol 9. 2021-03-05. PMID:33659254. |
herein, we found that cftr knockout mice exhibited insulin resistance and glucose tolerance. |
2021-03-05 |
2023-08-13 |
mouse |
| Junzhong Gu, Weiwei Zhang, Lida Wu, Yuchun G. CFTR Deficiency Affects Glucose Homeostasis via Regulating GLUT4 Plasma Membrane Transportation. Frontiers in cell and developmental biology. vol 9. 2021-03-05. PMID:33659254. |
furthermore, we demonstrated insulin-induced glucose transporter 4 (glut4) translocation to the cell membrane was abnormal in the cftr knockout mice muscle fibers, suggesting that defective intracellular glut4 transportation may be the cause of impaired insulin responses and glucose homeostasis. |
2021-03-05 |
2023-08-13 |
mouse |
| Mauricio Di Fulvio, Marika Bogdani, Myrian Velasco, Timothy S McMillen, Cecilia Ridaura, Lisa Kelly, Mohammed M Almutairi, Shams Kursan, Abu A Sajib, Marcia Hiriart, Lydia Aguilar-Brya. Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet. PloS one. vol 15. issue 12. 2021-01-12. PMID:33264332. |
the later has proven difficult to determine due to low expression of cftr in β-cells, which results in the general perception that this cl-channel does not participate in the modulation of insulin secretion or the development of cfrd. |
2021-01-12 |
2023-08-13 |
mouse |
| Mauricio Di Fulvio, Marika Bogdani, Myrian Velasco, Timothy S McMillen, Cecilia Ridaura, Lisa Kelly, Mohammed M Almutairi, Shams Kursan, Abu A Sajib, Marcia Hiriart, Lydia Aguilar-Brya. Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet. PloS one. vol 15. issue 12. 2021-01-12. PMID:33264332. |
our results demonstrate heterogeneous cftr expression in human, mouse and rat β-cells and provide evidence that pharmacological inhibition of cftr influences basal and stimulated insulin secretion in normal mouse islets but not in islets lacking this channel, despite being detected by electrophysiological means in ~30% of β-cells. |
2021-01-12 |
2023-08-13 |
mouse |